Search Result

Results for "

cyclin+B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (74) Cyclin G-associated Kinase (GAK) (3) 5-HT Receptor (2) Akt (6) APC (3) Apoptosis (40) Aryl Hydrocarbon Receptor (2) ATM/ATR (1) Aurora Kinase (3) Autophagy (10) Bcl-2 Family (4) Bcr-Abl (2) c-Myc (2) Casein Kinase (1) Caspase (7) CFTR (1) Checkpoint Kinase (Chk) (2) DNA/RNA Synthesis (7) Drug Derivative (2) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (2) ERK (3) Ferroptosis (2) FGFR (1) Fungal (2) GSK-3 (23) HSP (4) IFNAR (1) Interleukin Related (1) IRE1 (2) JAK (2) JNK (4) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) MDM-2/p53 (9) MEK (3) Microtubule/Tubulin (6) Mitosis (2) MMP (1) Molecular Glues (2) mTOR (4) NF-κB (1) p38 MAPK (3) PAK (1) PANoptosis (2) Parasite (3) PI3K (2) Polo-like Kinase (PLK) (1) PROTACs (3) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (6) Reference Standards (9) STAT (4) TNF Receptor (1) Topoisomerase (2) VEGFR (3) Wee1 (1) Wnt (1) YAP (2) β-catenin (1)
By Research Areas:	Cancer (92) Infection (5) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (6)

By Targets:

CDK (74)

Cyclin G-associated Kinase (GAK) (3)

5-HT Receptor (2)

Akt (6)

APC (3)

Apoptosis (40)

Aryl Hydrocarbon Receptor (2)

ATM/ATR (1)

Aurora Kinase (3)

Autophagy (10)

Bcl-2 Family (4)

Bcr-Abl (2)

c-Myc (2)

Casein Kinase (1)

Caspase (7)

CFTR (1)

Checkpoint Kinase (Chk) (2)

DNA/RNA Synthesis (7)

Drug Derivative (2)

E1/E2/E3 Enzyme (1)

Epigenetic Reader Domain (2)

ERK (3)

Ferroptosis (2)

FGFR (1)

Fungal (2)

GSK-3 (23)

HSP (4)

IFNAR (1)

Interleukin Related (1)

IRE1 (2)

JAK (2)

JNK (4)

Ligands for Target Protein for PROTAC (1)

Lipoxygenase (1)

MDM-2/p53 (9)

MEK (3)

Microtubule/Tubulin (6)

Mitosis (2)

MMP (1)

Molecular Glues (2)

mTOR (4)

NF-κB (1)

p38 MAPK (3)

PAK (1)

PANoptosis (2)

Parasite (3)

PI3K (2)

Polo-like Kinase (PLK) (1)

PROTACs (3)

Raf (1)

Ras (1)

Reactive Oxygen Species (ROS) (6)

Reference Standards (9)

STAT (4)

TNF Receptor (1)

Topoisomerase (2)

VEGFR (3)

Wee1 (1)

Wnt (1)

YAP (2)

β-catenin (1)

By Research Areas:

Cancer (92)

Infection (5)

Inflammation/Immunology (5)

Metabolic Disease (2)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Targets Recommended: CDK Cyclin G-associated Kinase (GAK) CDKL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12529

Ro-3306 Maximum Cited Publications 67 Publications Verification	CDK Apoptosis	Cancer
Ro-3306 is a potent and selective inhibitor of CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

HY-10580

GSK 3 Inhibitor IX 15+ Cited Publications 6-Bromoindirubin-3'-oxime; BIO; MLS 2052	GSK-3 CDK Apoptosis	Cancer
GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and *CDK1-cyclinB* complex with IC₅₀s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.

HY-18340

(R)-CR8 1 Publications Verification CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-B0294

Flubendazole 5+ Cited Publications	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-12302

Kenpaullone 10+ Cited Publications 9-Bromopaullone; NSC-664704	CDK GSK-3	Cancer
Kenpaullone is a potent inhibitor of **CDK1/cyclin B and GSK-3β, with IC₅₀*s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin* A, CDK2/cyclin E, and CDK5/p25 with IC₅₀s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.

HY-172085

SH514	IFNAR DNA/RNA Synthesis c-Myc CDK	Cancer
SH514 is an orally active IRF4 inhibitor (IC₅₀ = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, *Cyclin B1, Cyclin* D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors .

HY-11012

TDZD-8 10+ Cited Publications GSK-3β Inhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of GSK-3β, with an IC₅₀ of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for *CDK1/cyclinB* and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) .

HY-N2424

Flavone 2-Phenyl-4-chromone	CDK Apoptosis Caspase	Cancer
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as *cyclin B1) and apoptosis-related factors (such as p21_waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B*1 protein expression, upregulates p21_waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .

HY-10014

R547 2 Publications Verification	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-18299A

Purvalanol A 4 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-N0417

Cucurbitacin E 5+ Cited Publications α-Elaterin; α-Elaterine	CDK Autophagy PANoptosis	Metabolic Disease Inflammation/Immunology Cancer
Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the *cyclin B1/CDC2* complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors .

HY-19807

Indirubin-3'-monoxime 4 Publications Verification Indirubin-3'-oxime	GSK-3 CDK Lipoxygenase	Cancer
Indirubin-3'-monoxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC₅₀s of 22 nM and 7.8-10 µM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC₅₀s of 100 and 180 nM.

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, *cyclin B1-CDK1, cyclin* E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for **CDK1/cyclin B*, CDK2/cyclin* A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .

HY-117535

CDK2-IN-4 3 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-13468

KW-2478 4 Publications Verification	HSP Apoptosis Bcr-Abl p38 MAPK CDK STAT	Cancer
KW-2478 is an HSP90 inhibitor (IC₅₀ = 3.8 nM). KW-2478 inhibits the growth and induces apoptosis in chronic myeloid leukemia (CML) cells and liver cancer cells. KW-2478 weakens the BCR/ABL and MAPK signaling pathways, leading to increased p27 and p21 expression and decreased cyclin B1 expression. KW-2478 downregulates STAT3 expression. KW-2478 may be used in research on cancers such as CML and liver cancer .

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, *cyclin B1-CDK1, cyclin* E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and *CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for **CDK1/cyclin B** and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively .

HY-18299

Purvalanol B 2 Publications Verification NG 95	CDK Parasite	Infection Cancer
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for **cdc2-cyclin B*, CDK2-cyclin* A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

HY-W011428

Olomoucine 1 Publications Verification	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 μM), CDK/p35 kinase (IC₅₀=3 μM) and ERK1/p44 MAP kinase (IC₅₀=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-103221

MeBIO	Aryl Hydrocarbon Receptor GSK-3 CDK	Others
MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC₅₀ of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively .

HY-111930

5-Iodo-indirubin-3'-monoxime	GSK-3 CDK	Cancer
5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and **CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC₅₀**s of 9, 20 and 25 nM, respectively .

HY-115565

CGP-74514	CDK Apoptosis	Cancer
CGP-74514 (Compound 13) is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC₅₀=25 nM). CGP-74514 inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G₂/M phase and induces tumor cell apoptosis. CGP-74514 is promising for research of bladder cancer .

HY-130841

Apcin-A	APC Ligands for Target Protein for PROTAC	Cancer
Apcin-A is a small molecule inhibitor that selectively targets the cell division cycle protein Cdc20 and is a derivative of Apcin (HY-110287). Apcin-A competitively binds to the D-box binding pocket of Cdc20 and inhibits substrate ubiquitination mediated by the anaphase promoting complex APC/C-Cdc20. Apcin-A also blocks the binding of Cdc20 to substrates (such as securin and cyclin B1), inhibiting anaphase initiation and cell cycle exit. Apcin-A can promote or prolong mitotic slippage in coordination with p31 ^comet under conditions of high spindle assembly checkpoint (SAC) activity. Apcin-A can be used to develop anti-mitotic drugs and overcome tumor chemotherapy resistance. Apcin-A can be used to synthesize PROTAC CP5V (HY-130257)[1][2][3].

HY-18340A

(R)-CR8 trihydrochloride 1 Publications Verification CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .

HY-112462

Cdk1/2 Inhibitor III	CDK	Cancer
Cdk1/2 Inhibitor III (compound 3n) is a highly potent and selective **Cdk1/cyclin B** and Cdk2/cyclin A inhibitor of with IC₅₀s of 0.6 nM and 0.5 nM, respectively. Cdk1/2 Inhibitor III shows selectivity over VEGF-R2 (IC₅₀ of 32 nM), GSK-3β (IC₅₀ of 140 nM), and a other kinases. Cdk1/2 Inhibitor III inhibits in cell proliferation with IC₅₀s of 20 nM, 35 nM and 92 nM for HCT-116, HeLa, and A375 cells, respectively .

HY-N3000

6-Methoxydihydrosanguinarine	JNK IRE1 Akt mTOR YAP Reactive Oxygen Species (ROS) Autophagy Apoptosis Ferroptosis Fungal	Infection Inflammation/Immunology Cancer
6-Methoxydihydrosanguinarine is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer .

HY-15612

CDK4-IN-1	CDK	Cancer
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

HY-114903

(E/Z)-BIO-acetoxime GSK-3 Inhibitor X	GSK-3 CDK	Neurological Disease Metabolic Disease Cancer
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and **CDK1/cyclin B (IC₅₀**=2.4, 4.3, 63 μM) .

HY-155552

GSPT1 degrader-1	Apoptosis CDK Caspase	Cancer
GSPT1 degrader-1 is a highly selective degrader targeting GSPT1. GSPT1 degrader-1 induces degradation via the ubiquitin-proteasome system. GSPT1 degrader-1 induces G₀/G₁ phase arrest, apoptosis (apoptosis) and inhibits proliferation in leukemia cells. GSPT1 degrader-1 reduces the levels of CDK6 and *Cyclin B1, while increases the levels of activated caspase-3* and caspase-9 in leukemia cells. GSPT1 degrader-1 can be used in leukemia research .

HY-P2480

Histone H1-derived Peptide	CDK	Others
Histone H1-derived Peptide is a phosphopeptide and the peptide substrates containes a sequence in accordance with the optimal recognition motif for CDK, can be used to detecting CDK1-cyclinB1 enzyme activity .

HY-143328

PROTAC BRD4 Degrader-17	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BRD4 Degrader-17 (compound 13i) is a potent PROTAC BRD4 Degrader, with IC₅₀ values of 29.54 nM (BRD4 (BD1)) and 3.82 nM (BRD4 (BD2)). PROTAC BRD4 Degrader-17 significantly attenuates G2/M progression associated *Cyclin B1* expression. PROTAC BRD4 Degrader-17 significantly induces apoptosis in MV-4-11 cells .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and *CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-164906

TMX-2138	CDK PROTACs	Cancer
TMX-2138 is a CDKs PROTAC degrader, with IC₅₀s of 8.7 nM, 10.9 nM, 7.0 nM and 25.7 nM for CDK1/cyclinB, CDK2/cyclinA, CDK5/p25 and CDK9/cyclinT1, respectively. TMX-2138 promotes ubiquitination and degradation of CDKs. TMX-2138 can be used for the research of ovarian cancer (Pink: CDKs ligand (HY-151071); Blue: E3 ligase CRBN ligand (HY-14658); Black: linker (HY-W008352)) .

HY-112336

Aloisine RP106	CDK GSK-3	Neurological Disease
Aloisine RP106 (compound 38) is a potent inhibitor of **Cdk1/cyclin B, Cdk5/p25, and GSK3 with IC₅₀**s of 0.70µM, 1.5µM, 0.92 µM, respectively .

HY-118976

CGP-74514 hydrochloride CGP-74514A	CDK Apoptosis	Cancer
CGP-74514 hydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC₅₀: 25 nM). CGP-74514 hydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G₂/M phase and induces tumor cell apoptosis. CGP-74514 hydrochloride is promising for research of bladder cancer .

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent CDK inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-146817

Tubulin polymerization-IN-11	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-11 is a potent tubulin polymerization inhibitor with an IC₅₀ value of 3.4 μM. Tubulin polymerization-IN-11 shows antiproliferative activity. Tubulin polymerization-IN-11 induces Apoptosis and cell cycle arrest at G2/M phase. Tubulin polymerization-IN-11 decreases the expression of cyclin B1, p-cdc2, and Bcl-2 protein levels and increases the expression of cleaved PARP .

HY-E70653

CDK1/CycB1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycB1 Recombinant Human Active Protein Kinase is an ortholog of CDK1. CDK1/cyclin B1 complexes initiates mitotic entry by phosphorylating a multitude of proteins to condense chromosomes, disrupt the nuclear envelope, and enable microtubules polymerization to attach and to segregate the chromosomes .

HY-B0294R

Flubendazole (Standard)	Reference Standards Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-13468A

KW-2478 hydrochloride	HSP Apoptosis Bcr-Abl p38 MAPK CDK STAT	Cancer
KW-2478 hydrochloride is an HSP90 inhibitor (IC₅₀ = 3.8 nM). KW-2478 hydrochloride inhibits the growth and induces apoptosis in chronic myeloid leukemia (CML) cells and liver cancer cells. KW-2478 hydrochloride weakens the BCR/ABL and MAPK signaling pathways, leading to increased p27 and p21 expression and decreased *cyclin B1* expression. KW-2478 hydrochloride downregulates STAT3 expression. KW-2478 hydrochloride may be used in research on cancers such as CML and liver cancer .

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM) .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-N0417R

Cucurbitacin E (Standard) α-Elaterin (Standard); α-Elaterine (Standard)	Reference Standards CDK Autophagy PANoptosis	Cancer
Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-103383

(R)-DRF053 dihydrochloride	CDK Casein Kinase	Neurological Disease Cancer
(R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), **CDK1/cyclin B and CDK5/p25 inhibitor with IC₅₀**s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .

HY-110359

CGP-74514 dihydrochloride	CDK Apoptosis	Cancer
CGP-74514 dihydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC₅₀=25 nM). CGP-74514 dihydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G₂/M phase and induces tumor cell apoptosis. CGP-74514 dihydrochloride is promising for research of bladder cancer .

HY-143327

PROTAC BRD4 Degrader-16	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BRD4 Degrader-16 is a potent PROTAC BRD4 Degrader, with IC₅₀ values of 34.58 nM (BRD4 (BD1)) and 40.23 nM (BRD4 (BD2)). PROTAC BRD4 Degrader-16 ignificantly attenuates G2/M progression associated *Cyclin B1* expression. PROTAC BRD4 Degrader-16 significantly induces apoptosis in MV-4-11 cells .

HY-161521

PLK1-IN-10	Polo-like Kinase (PLK)	Cancer
PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death .

Cat. No.	Product Name	Target	Research Area

HY-P2480

Histone H1-derived Peptide	CDK	Others
Histone H1-derived Peptide is a phosphopeptide and the peptide substrates containes a sequence in accordance with the optimal recognition motif for CDK, can be used to detecting CDK1-cyclinB1 enzyme activity .

Host:	Mouse (3) Rabbit (6)
Reactivity:	Human (9) Rat (5) Mouse (2)
Application:	IHC-P (4) ICC/IF (7) IP (6) IHC-F (1) WB (9) FC (3) ELISA (5)
Isotype:	IgG (6) IgG1 (2)
Conjugation:	Non-conjugated (9)
Clonality:	Polyclonal (1) Monoclonal (5) Monoclonal Antibody (1) Recombinant (3)
Modification:	Phosphorylated (2) Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80632

	Cyclin B1 Antibody CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	Cyclin B1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cyclin B1.

HY-P85113

	Cyclin B1 Antibody (YA4805) CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IP, ICC/IF, FC, ELISA	Human, Rat
	Cyclin B1 Antibody (YA4805) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Cyclin B1.

HY-P80097

	Cyclin B1 Antibody (YA486)	WB, ICC/IF, IHC-P, IP	Human
	Cyclin B1 Antibody (YA486) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cyclin B1.

HY-P80998

	Cyclin B2 Antibody (YA4635)	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	Cyclin B2 Antibody (YA4635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cyclin B2.

HY-P80806

	*Phospho-Cyclin B1 (Ser126) Antibody (YA208)* CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IP	Human
	Phospho-Cyclin B1 (Ser126) Antibody (YA208) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cyclin B1 (Ser126).

HY-P86525

	*Phospho-Cyclin B1(Ser126) Antibody (YA6217)* CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IHC-P, ICC/IF, IP, ELISA	Human
	Phospho-Cyclin B1(Ser126) Antibody (YA6217) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cyclin B1(Ser126).

HY-P80806A

	*Phospho-Cyclin B1 (Ser126) Antibody (YA208)(PBS only)* CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IP	Human
	Phospho-Cyclin B1 (Ser126) Antibody (YA208) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cyclin B1 (Ser126).

HY-P84097

	Cyclin B1 Antibody (YA3794) CCNB; CCNB1	WB, ICC/IF, FC, ELISA	Human, Rat
	Cyclin B1 Antibody (YA3794) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin B1.

HY-P84097A

	Cyclin B1 Antibody (YA3794)(PBS only) CCNB; CCNB1	WB, ICC/IF, FC, ELISA	Human, Rat
	Cyclin B1 Antibody (YA3794) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin B1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks